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Summary We have studied alterations in glutathione (GSH) levels and glutathione-S-transferase (GST)
activity in a series of in vitro derived multidrug resistant and cisplatin resistant sublines of the human lung
cancer lines NCI-H69 (small cell), COR-L23 (large cell) and MOR (adenocarcinoma). We have also investi-
gated the effects of ethacrynic acid, a putative inhibitor of GSTs, on levels of GSH and GST activity and on
cellular sensitivity to melphalan and to cisplatin.
Neither GSH content nor GST activity were significantly greater in the resistant sublines compared with
their respective parental lines. The only effects of treating with ethacrynic acid at doses of 1 lag ml-I and
3 fig ml-I for 2 h were a reduction in GSH content in the cisplatin resistant subline H69/CPR at the 3 fig ml'l
dose, and an increase to over 140% of control at 1 fig ml-' and 3 fig ml- ' in the MOR parental line (MOR/P)
and at I tg ml-' in the multidrug resistant subline MOR/R. Exposure of parental line COR-L23/P to
3 ltg ml-' and 6 Lig ml- of ethacrynic acid for 24 h, however, increased the GSH content to over 300% and
500% of control respectively.
Variable effects of ethacrynic acid on GST activity were seen in these cell lines. Doses of 1 fig ml- and
3 tig ml-' reduced activity to 59% and 48% of control respectively in multidrug resistant subline H69/LX4.
On the other hand, activity was increased in the cisplatin resistant subline H69/CPR (to 146% and 218% of
control) and in MOR/P (to 117% and 137% of control) by 1 jg ml- and 3 jig ml-' respectively of ethacrynic
acid.
Addition of ethacrynic acid (3 lag ml-') to treatment of the cell lines with melphalan or with cisplatin did
not alter the dose-response curves to these agents.
The intrinsic or acquired resistance of many tumours to
chemotherapy is a major obstacle to the successful treatment
of cancer. A number of mechanisms of cellular resistance
have been shown to confer cross-resistance to groups of
cytotoxic drugs (Moscow & Cowan, 1988). One such
mechanism which leads to resistance to alkylating agents in
cell lines involves elevated levels of glutathione (GSH) or
changes in the activity of enzymes involved in GSH
biochemistry (Meister & Griffith, 1979; Dulik et al., 1986).
The tripeptide GSH is the principal intracellular non-
protein thiol. The roles of GSH in cellular metabolism in-
clude protection from oxygen intermediates under aerobic
metabolism and detoxification of metabolites (for review see
Arrick & Nathan, 1984). It has been known for many years
that thiols can protect cells from the toxicity of ionising
radiation and alkylating agents (for review see Connors,
1966). Meister and Griffith (1979) suggested that reducing
cellular GSH may be an approach to increasing the sensi-
tivity of cells to alkylating agents. A number of workers have
subsequently described cell lines in which drug resistance is
associated with increased levels of cellular GSH and where
reduction of GSH can restore drug sensitivity (Suzukake,
1982; Hamilton et al., 1985; Batist et al., 1986).
The detoxification of alkylating agents by GSH occurs via
direct conjugation of the thiol group and the reactive
alkylating group (Connors, 1966). This reaction is catalysed
by a group of enzymes known as glutathione-S-transferase
(GSTs) (Boyland & Chasseaud, 1969; Habig et al., 1974).
The GSTs also form covalent interactions with reactive
metabolites of certain carcinogens resulting in detoxification
(Singer & Litwack, 1971; Ketterer & Beale, 1971; Chasseaud,
1979). Soluble GSTs have been separated into three classes,
alpha (basic), mu (neutral), and pi (acidic) on the basis of
structural, immunological, and enzymatic properties (Man-
nervik et al., 1985). Although studies have demonstrated
some overlap in isoenzyme substrate specificity, the differential
GST isoenzyme profiles of cell lines from different species
and/or different tissues are likely to lead to variability of
action against various substrates.
A number of cell lines made resistant in vitro to cytotoxic
drugs have been shown to display increased GST activity.
For example Wang and Tew (1985) found 2-5-fold elevated
GST levels in a Walker 256 cell line made resistant to
chlorambucil, compared to the sensitive line. Similar results
have been found for cell lines resistant to cyclophosphamide
(McGown & Fox, 1986), Adriamycin (Batist, 1986), and
mitomycin C (Taylor, 1986). GST pi was found to be
elevated in a series of drug resistant sublines of a human
malignant melanoma cell line. This elevation did not however
confer cross resistance to drugs used for the selection of
other resistant sublines which also exhibited GST pi. (Wang
et al., 1989). Activity of GSTs have also been found to be
increased in human ovarian tumour tissues which are resis-
tant to chemotherapy (Wolf et al., 1985).
The transfection of genes encoding for human pi and alpha
class GSTs into yeast cells has been shown to confer resis-
tance to chlorambucil (Black et al., 1989). Human GST pi
genes have also been transfected into mammalian cells and
found to confer resistance to known substrates of this class,
such as ethacrynic acid, but not to anti-tumour agents such
as cisplatin and melphalan (Moscow et al., 1989). Puchalski
and Fahl (1990) transfected rat alpha and mu class GST
genes, as well as human pi class. The rat mu class conferred
the greatest (albeit modest) resistance to cisplatin (1.5-fold).
Inhibitors of GST activity have been a focus of study as a
possible means of reducing resistance (Mannervik & Daniel-
son, 1988). One compound of particular interest has been
ethacrynic acid, a clinically used diuretic agent (Tew et al.,
1988). Ethacrynic acid has been shown to increase cell kill by
chlorambucil or melphalan in Walker 256 and HT29 in vitro
(Tew et al., 1988) and human tumours xenografted into nude
mice (Clapper et al., 1990).
In this paper we describe experiments designed to investi-
gate the possible role of GSH and/or GST activity in inherent
or acquired resistance of human lung cancer cell lines. We
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then examine the effects of ethacrynic acid upon GSH, GST
and sensitivity to melphalan or cisplatin.
Materials and methods
Cell lines and culture conditions
The NCI-H69 human small cell lung cancer line (hereafter
referred to as H69/P) originally supplied by Drs D. Carney
and A. Gazdar (NCI/Navy Medical Oncology Branch,
Bethesda, MD, USA) was grown as floating aggregates in
RPMI 1640 medium (Gibco Biocult, Paisley, UK) supple-
mented with 10% foetal calf serum (Seralab, Crawley Down,
UK), penicillin and streptomycin (at concentrations of
100 IU ml-' and 100 Lgml-' respectively). Stock cultures
were maintained in 75 cm2 tissue-culture flasks (Falcon Plas-
tics, Cambridge, UK) at 37°C in an atmosphere of 92% air
and 8% CO2. The large cell lung cancer line, COR-L23
(L23/P) (Baillie-Johnson et al., 1985) and the adenocar-
cinoma line MOR (MOR/P) (supplied by Dr M. Ellison,
Ludwig Inst. Sutton Branch) were grown as monolayers on
plastic and were maintained under the same medium and
culture conditions as H69/P. Subculture of H69/P and resis-
tant sublines was achieved by mechanical dissagregation and
transfer of small groups of cells to new flasks, whereas for
L23/P, MOR/P and resistant sublines, the use of 0.4% tryp-
sin plus 0.02% versene was required.
Drug resistant sublines
The drug resistant sublines of the H69/P, L23/P and MOR/P
lines were maintained under the same culture conditions as
the parent lines, except for the addition ofvarious concentra-
tions of drugs to the growth medium. Drug resistance was
developed in each case by the addition of a stepwise increase
in drug concentration to the growth medium of the parental
line as previously described. The H69/LX4 subline, an MDR
cell line which exhibits an 85-fold resistance to Adriamycin
(Twentyman et al., 1986) and hyperexpresses P-glycoprotein
(Reeve et al., 1989) was maintained at 0.4jgml-' of
Adriamycin. The H69/CPR subline, which exhibits a 5-fold
resistance to cisplatin and is cross resistant to melphalan
(Twentyman et al., 1991) was maintained in cisplatin at a
concentration of 0.4jg ml -. L23/R, a subline which ex-
presses an MDR phenotype without hyperexpression of P-
glycoprotein (Twentyman et al., 1986; Reeve et al., 1990) and
which is 20-fold resistant to Adriamycin, was grown in
0.2lag ml -' Adriamycin and L23/CPR, which exhibits a
3-fold resistance to cisplatin and is cross resistant to mel-
phalan (Twentyman et al., 1991) was grown in 0.05fg ml
cisplatin. MOR/R which also expresses an MDR phenotype
without P-glycoprotein hyperexpression (Twentyman et al.,
1986 and unpublished) exhibits a 10-fold resistance to
Adriamycin and was maintained in 0.2fg ml -' ofAdriamycin
and MOR/CPR which exhibits a 4-fold resistance to cisplatin
and is cross resistant to melphalan (Twentyman et al., 1991)
was maintained in 1 lAg ml -' cisplatin. All resistant cells were
grown in drug-free medium for at least 3 days before use in
experiments.
Drugs
Ethacrynic acid (Sigma, Poole, UK) was dissolved in
absolute ethanol. Melphalan (Wellcome Foundation Ltd,
London, UK) was dissolved in acidified ethanol. These two
agents were freshly prepared immediately before use and the
final concentration of ethanol in the medium did not exceed
0.2%. Cis-diamminedichloroplatinum (II) (cisplatin) (Lederle,
Gosport, UK) was dissolved in distilled water and aliquots
were stored at - 20°C. Drug was added to cells immediately
following thawing. Appropriate solvent controls were used in
all experiments.
Biochemical assays
Cells of the L23 and MOR parent and resistant lines, were
subcultured from stock flasks and inoculated into 25 cm2
flasks 4 days before experiments. Cells were in exponential
growth at the time of assay and a medium change was
carried out 24 h before assay. Ethacrynic acid was added to
produce a range of final concentrations and after 2 h (except
where a time course was being studied) the monolayer was
rinsed three times with PBS and cells then disaggregated and
counted as above.
Cultures of H69/P and resistant sublines in exponential
phase of growth, containing aggregates of various sizes, were
pipetted well in order to break up the aggregates, and
medium changed 24 h before assay. This resulted in cultures
containing single cells and small groups ofcells at the time of
assay. Immediately before drug treatment, a sample of the
culture was removed, disaggregated into a single cell suspen-
sion using 15 min incubation with 0.4% trypsin and 0.02%
versene and a count carried out. On the basis of the count
the bulk culture was diluted and aliquots were transferred
into 10ml of plastic centrifuge tubes for experiments. The
cells were treated for 2 h with various concentrations of
ethacrynic acid and then rinsed three times with PBS by
centrifugation.
GSH assay (oxidised and reduced) Cells were transferred
into plastic centrifuge tubes, rinsed three times with ice-cold
PBS and lysed using 100% TCA. They were then centrifuged
at 4°C (l1,000 g for 10min) and the supernatant was then
removed and used for total GSH analysis by the method of
Tietze (1969). Protein was removed by five cycles of diethyl
ether extraction followed by the complete evaporation of
diethyl ether from the sample. The reaction mixture consisted
of 5,5' dithio-bis-(2-nitrobenzoic acid) (DTNB), 0.15 ltmole
in 100jil, nicotinamide adenine dinucleotide phosphate
(reduced form) (NADPH), 0.2ftmole in 100jil, glutathione
reductase (1 unit in 50I1), the sample, blank or standard in a
50p1 volume and all made up to 1 ml with phosphate EDTA
buffer pH 7.5. The reaction took place at 30°C and the rate
of colour development was read at 412 nm over a period of
6 min. All reagents were obtained from Sigma (Poole, UK).
GST assay Assay for GST was carried out by the method
of Habig et al. (1974) using 1-chloro-2,4-dinitrobenzene as a
substrate. Cells were sonicated, centrifuged at 18,000g for
20 min, and the supernatant used for the kinetic studies.
Reaction mixture consisted of 940p1 of 1 mM CDNB (made
up by dissolving in 4 ml ethanol and adding drop by drop to
196 ml 0.1 M phospate buffer pH 6.5), 50il of 20 mM GSH
dissolved in distilled water, and 10j1 sample. The colour
development was read at 340 nm over a 2 min period at
25°C. All reagents were obtained from Sigma (Poole, UK).
Protein assay Total cytosolic protein determinations were
carried out, following sonication of cells, by the Bicin-
choninic acid assay (BCA), using a kit from Pierce (Luton,
UK) (Smith et al., 1985).
Chemosensitivity assays
Cellular response to treatment with ethacrynic acid or with
cytotoxic drugs was determined either by the MTT colori-
metric assay or by clonogenic assay.
MTT assay The assay used was based on that described by
Mosmann (1983), and modified in this laboratory (Twenty-
man & Luscombe, 1987). Cells were plated into 96-well
microtitre plates (Falcon Plastics, Cambridge, UK) at 4 x 103
(H69/P), 5 x 103 (H69/LX4), 5 x 103 (H69/CPR), 1 x 103
(L23/P), 2 x 103 (L23/R), 4 x 103 (L23/CPR), 4 x 103 (MOR/
P), 6 x 103 (MOR/R), 5 x 103 (MOR/CPR) per well, in 200p1
medium. After a period ofapproximately 2 h incubation (8%
C02, 92% air, 37°C) 20 p1 of the appropriate concentration
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of plates were then incubated either for a period of 6 days
('continuous exposure') in a gassing incubator (8% C02,
92% air, 37C) or for 24 h followed by medium change,
including two rinsing cycles, and a further 5 days incubation
in drug free conditions.
At the end of the incubation period, 20 of a 5 mg ml-'
solution of 3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) (Sigma, Poole, UK) in PBS was
added to each well and the plates returned to the incubator
for a further 5 h. After this, plates containing cells which
grow as floating aggregates were centrifuged for 5 min at
400g in order to pack the floating aggregates to the bottom
of the wells, whilst plates from adherent lines were not
centrifuged. The bulk of the medium was removed from each
well using a Pasteur pipette connected to a vacuum line,
leaving 10-20 il medium per well. To each well was then
added 200 pl DMSO (BDH, Poole, UK) and the plates were
agitated on a plate shaker for 10 min. Optical densities were
then read at 540 nm and a reference wavelength of 690 nm
on a Titertek Multiskan MCC ELISA plate reader (Flow
Laboratories, Rickmansworth, UK). Results were expressed
as a fraction of control absorbances.
Clonogenic assay Cells were treated with drugs either in
monolayer (L23/P, L23/R, L23/CPR, MOR/P, MOR/R and
MOR/CPR) or as aggregates in suspension (H69/P, H69/
LX4, H69/CPR) as described in 'biochemical assays' (above).
The soft agar clonogenic assay used was that of Courtenay
and Mills, (1978) with some modification (Walls & Twenty-
man, 1985). Briefly, known numbers of cells were plated into
tubes in Ham's F12 medium without 0.3% agar and August
rat red blood cells. Tubes were gassed with 5% C02, 5% 02
and 90% N2 and sealed. Racks of tubes were placed into
plastic boxes which were in turn gassed and sealed. Tubes
were incubated at 37°C and fed weekly with Ham's F12
medium, for 2-3 weeks depending on the cell line. Excess
medium was removed from the tubes and agar plugs were
fixed with 3% formaldehyde in PBS. Colonies containing
>50 cells were counted by squashing each plus on a petri
dish and examining it with an inverted microscope.
Results
GSH content
GSH content was measured by the Tietze assay in H69/P,
L23/P, MOR/P and the drug resistant sublines, growing in
exponential phase (Table I). None of the resistant cell lines
showed significantly elevated levels of GSH. L23/R (multi-
drug resistant) contained half the amount of GSH present in
the line from which it was derived (L23/P). GSH content was
also reduced in the multidrug and cisplatin resistant sublines
of the MOR line, but these differences were not statistically
significant. There were large differences in GSH content
between the various parent lung cancer lines with MOR/P
having the highest content (approximately twice that of L23/P
and ten times higher than H69/P) on a per cell basis.
GSTactivity
Measurements of GST activity in cell lines in exponential
growth phase, by conjugation of CDNB, revealed increased
levels in the multidrug resistant subline of H69/P and further
increases in the cisplatin resistant subline, these increases
were however not statistically significant. Conversely, levels
in the multidrug resistant subline L23/R were significantly
reduced. There was also a reduction in the cisplatin resistant
line L23/CPR, but this was not statistically significant. The
MOR parent cell line showed 5.6-fold greater activity than
H69/P and 8.6-fold greater activity than L23/P but there
were no significant differences between the parent and resis-
tant lines MOR (Table I).
Effect ofethacrynic acid alone
Cells were exposed to various doses of ethacrynic acid either
throughout the 6 day assay or for 24 h followed by a further
5 days incubation after extensive rinsing. MTT data in Figure
1 show that the sensitivities of the parental and drug resistant
cell lines to ethacrynic acid were rather similar, except that
both the multidrug resistant (H69/LX4) and the cisplatin
resistant (H69/CPR) sublines of H69/P were more sensitive
than the parent line to the 24 h exposure. MOR lines were
more generally resistant than the others particularly in con-
tinuous exposure experiments.
In experiments in which cells were exposed to ethacrynic
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Table I GSH levels and GST activity in human lung cancer cell
lines
GSH
[ng (10' cells)-']
14.6 (3.7)
14.0 (4.4)
17.3 (7.9)
74.2 (30.2)
31.7 (13.2)
50.7 (14.3)
124.0 (52.7)
97.0 (59.7)
98.8 (24.4)
GST activity
[nmole CDNB conjugated
(mgprotein)-') (min) -']
63.7 (14.8)
86.3 (30.8)
108.6 (42.9)
41.6 (16.0)
9.2 (4.6)
16.3 (17.1)
359.0 (123.4)
396.0 (175.3)
385.5 (157.5)
1.0-
0.8-
0.6-
0.4
0.2-
0.0-
0
1.0
0.8
0.6
0.4
0.2
0.0
b
.1 1 10 100
DO 0.1 1 10 100
Ethacrynic acid (,ug ml-')
Figure 1 The effect of ethacrynic acid on parent (0), multidrug
resistant (0), and cisplatin resistant (0) human lung cancer cell
lines, NCI-H69 (a,b), COR-L23 (c,d), and MOR (e,f). Assessed in
a 6 day MTT assay following 24 h drug exposure (a,c,e) or
continuous drug exposure (b,d,f). Each point is based on four
replicate wells.
Cell line
H69/P
H69/LX4
H69/CPR
L23/P
L23/R
L23/CPR
MOR/P
MOR/R
MOR/CPR
Values are the means of typically five separate determinations,
numbers in brackets are standard deviations.
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acid (doses up to 10 tLg ml -') for 2 h followed by clonogenic
assay, reduction in cell survival to less than 50% of control
was not seen in any of the cell lines (data not shown).
Table II shows GSH levels or GST activity after treatment
of cells with ethacrynic acid at 1 or 3 ,.g ml -l for 2 h.
Glutathione levels were increased as a result of this treatment
in all cell lines except H69/CPR and MOR/CPR. The effect
of prolonging ethacrynic acid exposure on L23/P was that
levels of GSH were increased. The results in Figure 2 show
that doses of 3jig ml -l and 6ytg ml l increase levels to
three and five times the control respectively after 24 h
exposure. T-hese increased GSH levels were detected only
after at least 8 h exposure to ethacrynic acid.
The effect of 2 h ethacrynic acid treatment on GST activity
was very varied. Activity was decreased to less than 80% of
control in H69/P and H69/LX4 at 1 fg ml ' and also in
H69/LX4 at 3 jg ml -l. Conversely, activity was increased to
greater than 120% of control in H69/CPR at 1 jig ml -' and
in H69/CPR, L23/CPR and MOR/P at 3jig ml -'.
Effects ofethacrynic acid in combination with cisplatin and
melphalan
The results of typical combination experiments in which cells
were treated for 2 h with 31tg ml ethacrynic acid, with
either cisplatin or melphalan also present during the second
hour are summarised in Figures 3 to 5. It may be be seen
that no clear enhancement ofcytotoxic drug effects were seen
for any of the combinations. Combination of ethacrynic acid
with cisplatin and melphalan was studied in all cell lines on
Table II GSH levels and GST activity in human lung cancer cell
lines following treatment with ethacrynic acid for 2h at 1 or
3 ug ml'
GSH/cell (% control) GST activity (% control)
Cell line 1 igml-t' 3fgmlh' JtIgml- h 3 tLgml-t
69/P 119 102 74 119
H69/LX4 109 108 59 48
H69/CPR 111 65 146 218
L23/P 100 110 93 119
L23/R 131 125 110 111
L23/CPR 122 120 93 135
MOR/P 143 144 117 137
MOR/R 152 110 110 111
MOR/CPR 107 94 88 81
Values are the means of at least two separate determinations.
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Figure 3 The effect of treating L23 parent (a), multidrug resist-
ant (b) and cisplatin resistant (c) cell lines for I h either alone (m)
or in combination with ethacrynic acid (3glgml-') for 1 h before
and during melphalan exposure (0). Error bars show standard
errors based on Poisson errors in total colony count in three
replicate tubes.
at least two independent occasions, a total of 22 experiments.
No clear potentiation of melphalan or cisplatin was seen in
any of these experiments.
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Figure 2 The effect with time of exposure to ethacrynic acid at
3ygmlh (0) or 6gml-' (0) on the GSH content of the
L23/P cell line.
We commenced this study in the hope that the use of etha-
crynic acid would prove to be an effective means of overcom-
ing acquired resistance to melphalan and/or cisplatin in
human lung cancer cell lines and eventually in the clinic. The
data presented in this paper do not, however, support the
hypothesis that ethacrynic acid is able to increase the efficacy
of alkylating agent cytotoxicity and are therefore in marked
contrast to those reported previously by Tew et al. (1988) for
chlorambucil.
In the earlier study, it was found that (a) 2 h treatment
with 1 fig ml -I (3tM) ethacrynic acid could produce a
modest depletion in GST activity and GSH levels in a range
of cell lines and (b) the response to chlorambucil, present for
the second hour of such a pretreatment could be dramatically
enhanced by this dose of ethacrynic acid. It was particularly
noticeable that the enhancement in a resistant Walker
tumour cell line was much greater than in a sensitive line,
although the depletion of GST activity (in percentage terms)
was similar and the activity (measured using CDNB as sub-
strate) was 3.5-fold higher in the resistant line. In a subse-
quent paper, the same authors reported enhancement of
melphalan response by ethacrynic acid in human colon car-
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Figure 4 The effect of treating H69 parent (a,c) and cisplatin resistant (b,d) cell lines for I h with melphalan (ab) alone (0) or in
combinatin with ethacrynic acid (3 fig ml-') for I h before and during cytotoxic drug exposure (0). Error bars show standard error
based on Poisson errors in total colony count in three replicate tubes.
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Figure 5 The effects of treating MOR parent, multidrug resis-
tant and cisplatin resistant cell lines for I h with either 5 or
20 jig ml-' of cisplatin alone ( _ ) or in combination with
ethacrynic acid (3 jig ml-') for h before and during cisplatin
exposure ( M ). Error bars show standard errors based on Pois-
son errors in total colony count in three replicate tubes.
cinoma cells growing as xenografts in nude mice (Clapper et
al., 1990).
Interpretaton of the various data sets are complicated by a
number of factors. Firstly, there are potential effects of etha-
crynic acid on both GSH levels and GST activity. Each of
these factors is known to be independently involved in deter-
mining alkylating agent sensitivity. Tew et al. (1988)
reported that in HT29 colon carcinoma cells chronically
exposed to low dose ethacrynic acid, an elevation of GST
activity was seen, but that there was no increase in GSH.
Conversely, we found that a prolonged exposure to etha-
crynic acid leads to a clear increase in GSH levels in human
lung cancer cells after some hours. In order to minimise these
complicating effects we decided, as did Tew et al. (1988), to
concentrate on short time exposures in our combination
experiments.
We found the effects of 2 h exposure to ethacrynic acid to
be somewhat variable in terms of changes in GSH and GST
activity, despite our efforts to ensure that our cells were in
similar growth states in each experiment. Our data indicate
the effects to be cell line dependent. Whilst, for instance, we
saw a decrease in GST activity in the subline H69/LX4, we
saw an increase in a different subline, H69/CPR. Because of
the variability however, these differences do not reach statis-
tical significance.
The baseline levels of GSH and GST activity in the various
sublines need to be considered. Whereas none of the drug-
resistant sublines exhibit clear changes in GSH content from
their parent lines, several sublines show marked changes in
GST activity. The cisplatin (and melphalan) resistant subline
H69/CPR shows a 60% increase in GST activity compared
with its parent line, whilst L23/R (multidrug resistant) and
L23/CPR (cisplatin and melphalan resistant) show 4.5-fold
and 2.5-fold reductions respectively compared to the parent
line L23/P. We are uncertain as to whether or not these
changes are responsible to any extent for the changed drug
sensitivity profiles of these sublines. Preliminary unpublished
data obtained in collaboration with Dr Jonathan Harris and
0.1
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Professor Brian Ketterer indicate that levels of the GST pi
isoenzyme are elevated in our H69 and MOR multidrug
resistant and cisplatin resistant sublines compared with the
respective parent lines. In general, however, elevated GST pi
activity, brought about by transfection in mammalian cells
has not resulted in resistance to alkylating agents (Moscow et
al., 1989; Nakagawa et al., 1990). Furthermore, although
elevated GST pi expression was seen in cell lines made
independently resistant to melphalan and cisplatin, there was
no cross-resistance between the lines, implying that the GST
pi elevations were not causatively involved (Wang et al.,
1989). A more recent report by Leyland-Jones et al. (1991)
has demonstrated that transfection of GST alpha into human
breast cancer cells was also ineffective in producing resistance
to alkylating agents.
The ability of various GST isoenzymes to conjugate de-
toxification reactions between GSH and alkylating agents
also remains a matter of speculation (reviewed by Waxman,
1990). It is believed that nitrogen mustards such as chloram-
bucil and melphalan may be inactivated by such a metabolic
route and Dulik et al. (1986) have shown in vitro that such a
chemical reaction occurs. The in vivo significance of this
observation and the possible inclusion of cisplatin in the
group of compounds for which this metabolic process is
significant, however, remain unclear (Dedon et al., 1987).
Furthermore, the relative role played by different GST isoen-
zymes has not been investigated to any significant extent.
Given the large degree of uncertainty surrounding many of
these issues, it is perhaps not surprising that unexplained
differences in results may be obtained using ethacrynic acid
in different systems. The results of Tew et al. (1988) were
extremely encouraging as they not only showed a clear sen-
sitisation of cells to chlorambucil, but also showed a selective
effect in resistant cells. Recently, Hansson et al. (1991) have
shown a 2-fold sensitisation to melphalan in human
melanoma cells exposed to a much higher dose of ethacrynic
acid (20 LM) than that used by Tew et al. (1988). No data
were given for lower doses. In a study using primary cultures
of human tissues, Nagourney et al. (1990) observed that 1 JLM
ethacrynic acid was able to enhance the effects of doxorubi-
cin or nitrogen mustard only in lymphoid cells and not in
cells from other types of malignancy. In these experiments,
both the ethacrynic acid and the cytotoxic drug were present
continuously for 4 days.
Although our experimental conditions were quite similar to
those of Tew et al. (1988), we have been unable to detect any
sensitisation to either melphalan or cisplatin in a wide range
of cell lines. It is, of course, by no means certain that the
modest changes in GST activity seen by Tew et al. (1988)
were the cause of the dramatic increases in sensitivity to
chlorambucil. Ethacrynic acid is likely to have a range of
pharmacological effects in addition to GST depletion, one or
more of which could be involved. Differences between the
two systems include possible variations in the substrate
specificities of the cell lines and the use of different drugs. A
more detailed analysis of the systems used by Tew et al.
would appear to us to be the most constructive approach
towards an understanding of their results and the possible
significance for clinical therapy.
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